Probability of non-response during interferon therapy in patients with chronic hepatitis C

Hepato-Gastroenterology

Volumn 46, Issue 27, 1999, Pages 1928-1936

  Testa, Roberto ^a,b   Giannini, Edoardo ^a   Picciotto, Antonino ^a   Risso, Domenico ^b   Caglieris, Sergio ^a   Fasoli, Alberto ^a   Lantieri, Pasquale Bruno ^b   Icardi, Gian Carlo ^b   Lapertosa, Gabriella ^b   Celle, Guido ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Chronic hepatitis C; Gamma glutamyltransferase; Hepatitis C virus genotype; Interferon therapy; Monoethylglycinexylidide

Indexed keywords

ALANINE AMINOTRANSFERASE; DEETHYLLIDOCAINE; GAMMA GLUTAMYLTRANSFERASE; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; CHRONIC HEPATITIS; CLINICAL TRIAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; HEALTH CARE COST; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROBABILITY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT FAILURE;

EID: 0032767982     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Davis GL: Prediction of response to Interferon treatment of chronic hepatitis C. J Hepatol 1994; 21:1-3.
2. Conjeevaram HS, Everhart JE, Hoofnagle JH: Predictors of a sustained beneficial response to interferon alpha therapy in chronic hepatitis C. Hepatol 1995; 22:1326-1329.
3. Tsubota A, Chayama K, Ikeda K, et al: Factors predictive of response to interferon-a therapy in hepatitis C virus infection Hepatol 1994; 19:1088-1094.
4. Chemello L, Bonetti P, Cavalletto L, et al: Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatol 1995; 22:700-706.
5. Yamada G, Takatani M, Fumitoshi K, et al: Efficacy of interferon alpha therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatol 1995; 22:1351-1354.
6. Booth JCL, Foster GR, Kumar U, et al: Chronic hepatitis C virus infections: predictive value of genotype and level of viraemia on disease progression and response to interferon α. Gut 1995; 36:427-432.
7. Camps J, Crisostomo S, Garcia-Granero M, et al: Prediction of the response of chronic hepatitis C to interferon alpha: a statistical analysis of pretreatment variables. Gut 1993; 34:1714-1717.
8. Pagliaro L, Craxi A, Cammaa C, et al: Interferon-α for chronic hepatitis C an analysis of pretreatment clinical predictors of response. Hepatol 1994; 19:820-828.
9. Izumi N, Enomoto N, Uchihara M, et al: Hepatic iron contents and response to interferon-a in patients with chronic hepatitis C. Relationship to genotypes of hepatitis C virus. Dig Dis Sci 1996; 41(5):989-994.
10. Serfaty L, Giral P, Loria A, et al: Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 1994, 21:12-17.
11. Van Thiel DH, Friedlander L, Malloy P, et al: γ-glutamyl transpeptidase as a response predictor when using α-interferon to treat hepatitis C. Hepato-Gastroenterol 1995; 42:888-892.
12. Mihm S, Hartmann H, Fayyazi A, et al: Preferential virological response to interferon-α2a in patients with chronic hepatitis C infected by virus genotype 3a and exhibiting a low γ-GT/ALT ratio. Dig Dis Sci 1996; 41(6):1256-1264.
13. Myabayashi C, Higuchi K, Aiba N, et al: Prediction of response to interferon therapy by serum levels of type IV collagen and prolyl hydroxylase in chronic hepatitis C. Int Hepatol Commun 1994; 2:156-160.
14. Yabu K, Kyosawa K, Mori H, et al: Serum collagen type TV for the assessment of fibrosis and resistance to interferon therapy in chronic hepatitis C. Scand J Gastroenterol 1994; 29:474-479.
15. Karino Y, Toyota J, Sugawara M, et al: Early loss of serum hepatitis C RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C. Am J Gastroenterol 1997; 92:61-65.
16. Gavier B, Martinez-Gonzalez MA, Riezu-Boj JI, et al: Viremia after one month of interferon therapy predicts outcome in patients with chronic hepatitis C. Gastroenterol 1997; 113:1647-1653.
17. Yamakawa Y, Sata M, Suzuki H, et al: Monitoring of serum levels of HCV RNA in early phase of IFN therapy; as a predictive marker of subsequent response. Hepato-Gastroenterol 1998; 19:133-136.
18. Terrault N, Wright T: Interferon and hepatitis C. N Engl J Med 1995; 332:1509-1511.
19. Poynard T, Bedossa P, Chevallier M, et al: A comparison of three interferon alpha-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332:1457-1462.
20. Sherlock S: Antiviral therapy for chronic hepatitis C virus infection. J Hepatol 1995, 23(Suppl 2):3-7.
21. Angelico M, Gandin C, Pescarmona E, et al: Recombinant interferon-α and ursodeoxycholic acid versus interferon-α alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up. Am J Gastroenterol 1995; 90:263-269.
22. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-159.
23. Stuyver L, Rossau R, Wyseur A, et al: Typing of hepatitis C virus isolates and characterization of new subgenotypes using a line probe assay. J Gen Virol 1993; 74(Pt. 6): 1093-1102.
24. Simmonds P: Variability of hepatitis C virus. Hepatol 1995; 21:570-583.
25. Knodell RG, Ishak KG, Black WC, et al: A formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatol 1981; 1:431-435.
26. Scheuer PJ: Classification of chronic viral hepatitis a need for reassessment. J Hepatol 1991; 13:372-374.
27. Testa R, Campo N, Caglieris S, et al: Lidocaine elimination and monoethylglycinexylidide formation in patients with chronic hepatitis or cirrhosis. Hepato-Gastroenterol 1998; 19:154-159.
28. Siegel S, Castellan NJ Jr: Nonparametric statistics for the behavioral sciences. Mc Graw-Hill, New York 1988.
29. Pawlotsky JM, Roudot-Thoraval F, Bastie A, et al: Factors affecting treatment responses to interferon-a in chronic hepatitis C. J Infect Dis 1996; 174:1-7.
30. Sharara AT, Hunt CM, Hamilton JD: Hepatitis C. Ann Intern Med 1996, 125:658-668.
31. Pawlotsky JM: Measuring hepatitis C viremia in clinical samples: can we trust the assays? Hepatol 1997; 26:1-4.
32. Magrin S, Craxi A, Fabiano C, et al: HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (Southern Italy). J Hepatol 1996; 25:583-590.
33. Tsubota A, Kumada H, Chayama K, et al: Relationship between pretreatment viremia level and response to interferon-α therapy in chronic hepatitis C differs in viral type 1 and 2 infections. Dig Dis Sci 1996; 41:1925-1932.
34. Wasson JH, Sox HC, Nef RK, et al: Clinical prediction rules. Applications and methodological standards. N Engl J Med 1985; 313:793-799.
35. Coverdale S, Byth K, Field J, et al: Antipyrine clearance and response to interferon treatment in patients with chronic active hepatitis C. Hepatol 1995; 22:1065-1071.
36. Roffi L, Colloredo Mels G, Antonelli G, et al: Breakthrough during recombinant interferon alpha therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatol 1995; 21:645-649.